Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS) gapped down prior to trading on Tuesday after an insider sold shares in the company. The stock had previously closed at $31.01, but opened at $28.59. Hims & Hers Health shares last traded at $30.4870, with a volume of 18,685,922 shares.

Specifically, CFO Oluyemi Okupe sold 36,922 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total value of $956,279.80. Following the completion of the transaction, the chief financial officer directly owned 281,867 shares in the company, valued at approximately $7,300,355.30. This represents a 11.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 18,005 shares of the firm’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $27.83, for a total value of $501,079.15. Following the completion of the sale, the chief financial officer directly owned 270,046 shares in the company, valued at approximately $7,515,380.18. The trade was a 6.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HIMS. TD Cowen dropped their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $25.00 and gave the company a “neutral” rating in a report on Thursday, April 16th. Barclays upped their price target on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 11th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $31.86.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Pipeline / potential deal catalyst: Market chatter that HIMS’s peptide program and a possible Novo Nordisk tie-up are lifting sentiment and drawing momentum into the stock ahead of earnings. Traders are positioning for a strong catalyst-driven run. Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
• Positive Sentiment: News coverage amplifying momentum: Multiple outlets are highlighting the peptide/partner narrative, which can attract short-term flows and momentum traders into HIMS. RFK’s peptides push helps boost Hims & Hers stock 50% in one week
• Neutral Sentiment: Sector tailwind: Positive clinical readouts at biotech peers (e.g., Nektar) are creating a broader small?cap biotech rally that may be lifting HIMS even if the company hasn’t released new clinical data. This is a market?sentiment tailwind rather than company?specific proof. This Biotech Stock Soars on Hair Loss Trial Results. It Isn’t a Cure for Baldness.
• Neutral Sentiment: Upcoming earnings date: A May 11 earnings report is acting as a focal point for traders—expect increased volatility and that the release (and management commentary) will drive the next major move. Why Hims & Hers Health stock is surging Monday
• Neutral Sentiment: Analyst positioning: Recent broker notes show mixed adjustments to targets/ratings (mostly Hold/Neutral), so the fundamental analyst consensus remains cautious despite the rally. Monitor any fresh upgrades or target hikes after earnings. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Negative Sentiment: Insider selling: CFO Oluyemi Okupe sold multiple blocks of shares (total ~54,900 shares across Apr 6–17) under a pre?arranged Rule 10b5?1 plan. Because these were planned trades the signal is muted, but sizable insider sales can weigh on sentiment if momentum fades. SEC Form 4 – Insider Sale

Hims & Hers Health Stock Down 1.2%

The firm’s 50-day moving average price is $19.95 and its 200-day moving average price is $31.92. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market cap of $6.98 billion, a price-to-earnings ratio of 60.06, a price-to-earnings-growth ratio of 2.74 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the prior year, the company earned $0.11 EPS. The firm’s revenue was up 28.4% on a year-over-year basis. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. Norges Bank purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at approximately $62,153,000. Invesco Ltd. raised its stake in shares of Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after purchasing an additional 1,600,004 shares during the period. Clear Street Group Inc. acquired a new position in shares of Hims & Hers Health during the third quarter worth $87,372,000. Finally, Marex Group plc boosted its stake in shares of Hims & Hers Health by 162.2% in the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after purchasing an additional 1,496,707 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.